share_log

VP, CEO & Executive Director of CK Life Sciences Int'l. (Holdings) Lance Richard Lee Yuen Buys 1,253% More Shares

VP, CEO & Executive Director of CK Life Sciences Int'l. (Holdings) Lance Richard Lee Yuen Buys 1,253% More Shares

Ck Life Sciences Int'l. (Holdings)的副總裁、 CEO及執行董事Lance Richard Lee Yuen購買了1253%的股份。
Simply Wall St ·  2024/11/16 06:11

Potential CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) shareholders may wish to note that the VP, CEO & Executive Director, Lance Richard Lee Yuen, recently bought HK$969k worth of stock, paying HK$0.46 for each share. That certainly has us anticipating the best, especially since they thusly increased their own holding by 1,253%, potentially signalling some real optimism.

潛在的Ck生命科學國際(控股)公司(HKG:775)股東可能希望注意到,副總裁、首席執行官兼執行董事Lance Richard Lee Yuen最近購買了價值HK$969,000的股票,每股支付HK$0.46。這確實讓我們期待最好的結果,尤其是因爲他們因此將自己的持股增加了1,253%,這可能標誌着一些真正的樂觀情緒。

CK Life Sciences Int'l. (Holdings) Insider Transactions Over The Last Year

Ck生命科學國際(控股)公司過去一年的內部交易

Notably, that recent purchase by Lance Richard Lee Yuen is the biggest insider purchase of CK Life Sciences Int'l. (Holdings) shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of HK$0.45. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Lance Richard Lee Yuen was the only individual insider to buy during the last year.

值得注意的是,Lance Richard Lee Yuen最近的購買是我們在過去一年中看到的Ck生命科學國際(控股)公司股份的最大內部購買。這意味着一位內部人士願意以高於當前價格HK$0.45的價格購買股票。他們可能會對這筆購買感到後悔,但更有可能的是他們對公司看好。在我們看來,內部人士支付的股票價格非常重要。一般來說,當內部人士以高於當前價格的價格購買股票時,這會引起我們的注意,因爲這表明他們認爲這些股票值得購買,即使價格更高。Lance Richard Lee Yuen是過去一年唯一一位購買股票的個人內部人士。

Lance Richard Lee Yuen bought 2.30m shares over the last 12 months at an average price of HK$0.46. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Lance Richard Lee Yuen在過去12個月內以平均價格HK$0.46購買了230萬股。您可以在下面的圖表中查看過去一年公司的內部交易(包括公司和個人)。通過點擊下面的圖形,您可以看到每筆內部交易的詳細信息!

big
SEHK:775 Insider Trading Volume November 15th 2024
香港證券交易所:775 內幕交易成交量 2024年11月15日

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

內部人士正在購買的股票是無數的。如果您喜歡投資於較少知名公司,您可以查看此免費的公司列表(提示:內部人士一直在購買它們)。

Does CK Life Sciences Int'l. (Holdings) Boast High Insider Ownership?

Ck 生命科學國際(控股)是否擁有高比例的內幕持股?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. CK Life Sciences Int'l. (Holdings) insiders own 22% of the company, currently worth about HK$960m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

對於普通股東來說,查看公司內部人士持有的股份數量是值得的。通常,內部持股比例越高,內部人士越有可能被激勵來長期發展公司。Ck 生命科學國際(控股)的內幕人士持有公司22%的股份,目前根據最近的股價,價值約爲HK$96000萬。大多數股東會樂於看到這種內部持股,因爲這表明管理層的激勵與其他股東的利益保持一致。

So What Do The CK Life Sciences Int'l. (Holdings) Insider Transactions Indicate?

那麼,Ck 生命科學國際(控股)的內幕交易表明了什麼?

It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about CK Life Sciences Int'l. (Holdings). Looks promising! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 2 warning signs for CK Life Sciences Int'l. (Holdings) you should know about.

看到最近的內幕購買無疑是個好消息。對過去一年交易的分析也讓我們充滿信心。但是,對於公司虧損的事實,我們並沒有同樣的感覺。再加上高比例的內幕持股,這一分析表明內幕人士對Ck 生命科學國際(控股)相當看好。前景看好!雖然了解內幕人士的持股和交易狀況很好,但我們也確保在做出任何投資決定之前考慮面臨的風險。每家公司都有風險,我們發現Ck 生命科學國際(控股)有兩個你應該注意的警告信號。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論